TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or the “Company”) is pleased to announce the signing of a Space Act Agreement with NASA’s Johnson Space Center (JSC), Houston Texas, to collaborate on research on Calcifying Nanoparticles (CNP) and its nature and role in pathological calcification, including the detection and treatment of the pathogen. Since Astronauts may be more prone to an increased rate of pathological calcification while in a zero gravity environment, the collaboration will bring a new approach to NASA’s need to better understand the effects of long-term space travel on humans.
